A multi-pronged treatment strategy combining broadly neutralizing antibodies, antiretroviral therapy and a drug that blocks the HIV coreceptor CCR5 has limited the establishment of viral reservoirs in infant macaques, according to a study published in Nature Microbiology. The findings, reported by Sacha, Ordonez, Pandey and colleagues, address one of the central obstacles in HIV research: preventing infected cells from becoming long-lived reservoirs capable of reigniting infection when treatment is stopped. Although the work was conducted in an infant macaque model rather than in human children, it offers a detailed view of how interventions given around the earliest stages of infection may influence the future size and distribution of the reservoir.
Antiretroviral therapy, or ART, can suppress HIV replication to levels at which standard clinical tests detect little or no virus in the blood. Suppression, however, does not normally eliminate infection. Viral genetic material can persist inside resting or slowly dividing immune cells, particularly CD4-positive T cells. Some of these cells contain proviruses that are transcriptionally silent, allowing them to evade immune recognition and the effects of drugs that target active replication. When ART is interrupted, a fraction of these proviruses can resume expression and generate new rounds of infection. The reservoir is therefore established early, maintained over time and difficult to remove once it has matured.
The study focuses on the period immediately after exposure, when the virus is expanding through susceptible tissues and disseminating between anatomical compartments. During this stage, infection is not simply a matter of increasing viral concentration in the bloodstream. Virus can enter lymphoid tissues, seed cellular niches and establish infected cells before treatment has fully controlled replication. The researchers used infant macaques to examine whether attacking the virus through several complementary mechanisms could reduce that early seeding process. Infant animals are particularly relevant to pediatric HIV research because their developing immune systems, patterns of immune-cell trafficking and clinical treatment circumstances differ from those of adults.
The first component of the intervention was ART, which targets viral enzymes or processes required for productive replication. By interrupting new infection cycles, ART rapidly reduces the amount of circulating virus and limits the generation of additional infected cells. Its activity is strongest against replication that is actively taking place, but it does not directly remove every cell that already contains integrated viral DNA. This distinction explains why ART is indispensable for controlling HIV yet insufficient by itself to eradicate the infection. In the experimental strategy, ART provided the foundation for suppression while the other components were intended to improve immune control and prevent the virus from reaching additional target cells.
Broadly neutralizing antibodies, often called bNAbs, contributed a second layer of protection. Unlike antibodies that recognize only a narrow viral variant, bNAbs bind conserved structures on the HIV envelope protein, the molecular machinery the virus uses to attach to and enter host cells. By occupying vulnerable regions of the envelope, these antibodies can prevent entry into new cells. They may also label infected cells or virus particles for clearance through Fc-mediated immune mechanisms, although the effectiveness of those functions depends on antibody properties, viral sensitivity and the state of the host immune system. The use of bNAbs is especially valuable in an early-treatment setting because it may combine immediate antiviral activity with immune engagement.
The third component targeted CCR5, a chemokine receptor found on many of the CD4-positive cells that HIV uses as early entry points. Viruses that use CCR5, known as R5-tropic viruses, attach to CD4 and then engage CCR5 to complete entry into the cell. Blocking this receptor can make susceptible cells less accessible, potentially reducing the number of successful infection events while viral replication is being brought under control. CCR5 blockade does not remove proviruses that are already integrated, and it cannot necessarily prevent infection by viruses that use alternative coreceptors. Its value in the combination therefore lies in reducing opportunities for further spread during a narrow but biologically important window.
Together, the three interventions address different stages of the infection cycle. ART suppresses replication inside infected cells and prevents the production of new virus. bNAbs can neutralize extracellular virus before it enters target cells and may recruit immune effector cells against infected targets. CCR5 blockade changes the availability of a major cellular entry route. The study’s central result is that this combined pressure limited viral reservoir seeding more effectively than would be expected from relying on a single mechanism alone. The work supports the idea that the reservoir is not an instantaneous, fixed feature of infection, but a dynamic population whose size and composition can be influenced during the earliest phase of disease.
The infant macaque model also allows investigators to examine tissues that cannot be routinely sampled in human infants, including lymph nodes and other sites where infected cells may persist. Such analyses are important because a low level of virus in blood does not necessarily indicate that reservoir formation has been prevented elsewhere. Reservoir measurements can include the amount of viral DNA, the frequency of cells carrying inducible virus and the ability of virus to rebound after treatment withdrawal. These measurements do not always yield identical estimates: much of the viral DNA detected in cells may be defective, while some intact proviruses remain deeply silent. The significance of the study therefore lies not only in blood suppression, but in its assessment of how early combination therapy affects the underlying tissue reservoir.
The findings do not demonstrate that HIV infection can be cured, nor do they establish that the same regimen would be safe, practical or equally effective in human infants. Antibody dosing, drug penetration into tissues, viral resistance, the timing of treatment and the developing immune system could all influence outcomes. CCR5-directed drugs may be active only against particular viral populations, while bNAbs can lose potency if the virus carries envelope variants that escape recognition. Even when a reservoir is reduced, a small number of intact proviruses may be sufficient to cause rebound after therapy is stopped. Human studies would therefore need to determine whether early combination treatment produces durable benefits without adding unacceptable toxicity or complexity to pediatric care.
Nevertheless, the study strengthens a broader strategy for HIV remission: intervene before the reservoir is extensively distributed, suppress replication with ART, protect vulnerable cells from infection and recruit antibody-mediated defenses against the virus. The approach could be relevant to infants exposed to HIV around birth, for whom rapid diagnosis and immediate treatment are already critical. It also provides a framework for testing next-generation bNAbs, longer-acting antiretroviral formulations and therapies designed to alter viral entry or immune-cell susceptibility. By showing that reservoir establishment can be constrained through coordinated intervention in an infant model, the work shifts attention from treating a fully established reservoir to preventing its formation in the first place.
Subject of Research: Combination therapy to limit HIV viral reservoir seeding in an infant macaque model.
Article Title: Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV.
Article References: Sacha, J.B., Ordonez, T., Pandey, S. et al. Combination therapy with broadly neutralizing antibodies, antiretroviral therapy and CCR5 blockade limits viral reservoir seeding in infant macaque model of HIV. Nature Microbiology (2026). https://doi.org/10.1038/s41564-026-02444-x
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41564-026-02444-x
Keywords: HIV, viral reservoir, broadly neutralizing antibodies, antiretroviral therapy, CCR5 blockade, infant macaque model, HIV prevention, early treatment, viral suppression, HIV remission
Tags: broadly neutralizing antibodies in HIV treatmentCCR5 receptor blockade in HIV preventionchallenges in HIV cure strategiescombination therapies for HIV reservoir reductionearly intervention strategies in HIV infectionHIV research using macaque modelsHIV reservoir formation in infant macaquesimpact of antiretroviral therapy on viral persistencelong-term HIV reservoir suppressionmulti-pronged HIV treatment approachesprevention of HIV reinfection after treatment cessationrole of immune cells in HIV persistenceviral latency and transcriptional silence
